Journal
BIOMEDICINES
Volume 9, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/biomedicines9121910
Keywords
Alzheimer's disease; senile plaques; beta-amyloid protein; tau protein; diagnosis; biomarker; treatment; acetylcholinesterase inhibitors; immunotherapy
Categories
Funding
- Junta de Andalucia, Spain [P20-01293, PECART-0096-2020]
- Ministry of Science and Innovation, Spain [PID2020-117544RB-100]
Ask authors/readers for more resources
Alzheimer's disease is characterized by cognitive decline and memory loss, with the amyloid cascade hypothesis being the leading theory in its pathophysiology. Diagnosis is currently based on clinical parameters and fluid-based biomarkers, with treatment focusing on symptom control through pharmacological and nonpharmacological approaches. Further research is needed to identify new biomarkers and therapies to prevent progression of the disease.
Alzheimer's disease (AD) is the most common cause of dementia. It is characterized by cognitive decline and progressive memory loss. The aim of this review was to update the state of knowledge on the pathophysiological mechanisms, diagnostic methods and therapeutic approach to AD. Currently, the amyloid cascade hypothesis remains the leading theory in the pathophysiology of AD. This hypothesis states that amyloid-beta (A beta) deposition triggers a chemical cascade of events leading to the development of AD dementia. The antemortem diagnosis of AD is still based on clinical parameters. Diagnostic procedures in AD include fluid-based biomarkers such as those present in cerebrospinal fluid and plasma or diagnostic imaging methods. Currently, the therapeutic armory available focuses on symptom control and is based on four pillars: pharmacological treatment where acetylcholinesterase inhibitors stand out; pharmacological treatment under investigation which includes drugs focused on the control of A beta pathology and tau hyperphosphorylation; treatment focusing on risk factors such as diabetes; or nonpharmacological treatments aimed at preventing development of the disease or treating symptoms through occupational therapy or psychological help. AD remains a largely unknown disease. Further research is needed to identify new biomarkers and therapies that can prevent progression of the pathology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available